Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | TPMT | P51580 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | NEK2 | P51955 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.45 |
| ▸ | TUBB | P07437 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4640409 | 0.86 | LMNA (0.59) | RAB9ALMNAHTTMAPK1TPMT | |
| SCHEMBL4640519 | 0.84 | LMNA (0.52) | RAB9ALMNAHTTMAPK1TPMT | |
| SCHEMBL3216968 | 0.82 | TPMT (0.50) | RAB9ALMNAHTTMAPK1TPMT | |
| SCHEMBL4602264 | 0.81 | TPMT (0.51) | RAB9ALMNAHTTMAPK1TPMT | |
| SCHEMBL4640433 | 0.80 | FYN (0.41) | NEK2SMN1; SMN2TUBB4ATUBBTUBA3C | |
| SCHEMBL6614594 | 0.80 | LMNA (0.55) | RAB9ALMNAHTTMAPK1TPMT | |
| SCHEMBL4640436 | 0.79 | NR1H4 (0.54) | RAB9ALMNAMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6787352 | 0.79 | ALDH1A1 (0.55) | LMNAHTTGAASMN1; SMN2ACLY | |
| SCHEMBL31038313 | 0.79 | CA1 (0.58) | RAB9ALMNAHTTMAPK1CA1 | |
| SCHEMBL2037868 | 0.78 | RXRA (0.64) | RAB9AHTTTPMTCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934924-B1 | NOVEL DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-1057815-B1 | CYCLIC AMIDE COMPOUNDS | KOWA CO (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-6828316-B2 | Antiallergens | KOWA CO., LTD. (JP) | 2004-12-07 | — | — | US | disclosed |
| US-6645957-B2 | Useful in preventing and treating allergic immunological diseases; treating asthma, atopic dermatitis, allergic rhinitis, inflammatory large bowel disease, contact dermatitis | KOWA CO., LTD. (JP) | 2003-11-11 | — | — | US | disclosed |
| US-6576642-B2 | Inhibitors of the production of Ig E antibodies, antiallergens | KOWA CO., LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
| US-20030096828-A1 | Cyclic amide compound | KOWA CO., LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
| US-6448242-B1 | COMPOUND HAVING A STRONG INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY; ANTIALLERGENS | KOWA CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020042414-A1 | Diamide compound and medicine containing the same | KOWA CO., LTD. (JP) | 2002-04-11 | — | — | US | disclosed |
| US-6340682-B1 | FOR THERAPY OF ALLERGIC IMMUNOLOGICAL DISEASE IS SELECTED FROM ASTHMA, ALLERGIC RHINITIS, INFLAMMATORY LARGE BOWEL DISEASE OR CONTACT DERMATITIS | KOWA CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| US-20010039279-A1 | Diamide compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2001-11-08 | — | — | US | disclosed |
| US-6297283-B1 | EXCELLENT INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY AND ARE HENCE USEFUL AS ANTIALLERGIC AGENTS | KOWA CO., LTD. (JP) | 2001-10-02 | — | — | US | disclosed |
| EP-1057815-A1 | CYCLIC AMIDE COMPOUNDS | Kowa Co., Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-0934924-A1 | NOVEL DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO. LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| EP-0926138-A1 | DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO. LTD. (JP) | 1999-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039279-A1 | Diamide compounds and compositions containing the same | HRH4, HRH2, HRH1 | RAB9A 3203/4885LMNA 3779/4885HTT 1217/4885 |
| US-20030096828-A1 | Cyclic amide compound | CMA1, HRH2, HRH4 | RAB9A 4751/4885LMNA 3867/4885HTT 4814/4885 |
| US-20020042414-A1 | Diamide compound and medicine containing the same | HRH4, HRH2, HRH1 | RAB9A 4494/4885LMNA 4686/4885HTT 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.